Zepbound vs Trulicity: Real-World Evidence Comparison
Zepbound (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 receptor agonist FDA-approved for chronic weight management. Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes and for reducing cardiovascular events in adults with established cardiovascular disease or multiple risk factors. Tirzepatide is also marketed as Mounjaro for type 2 diabetes; Zepbound and Mounjaro contain the same active ingredient under different indications.
Tirzepatide produces substantially larger average weight loss than dulaglutide in published obesity and diabetes trials, and it carries an FDA obesity indication that dulaglutide does not. Dulaglutide, in contrast, has a completed cardiovascular outcomes trial showing a reduction in major adverse cardiovascular events (MACE) in people with type 2 diabetes and elevated cardiovascular risk, an outcome tirzepatide has not yet published for its own dedicated cardiovascular trial as of mid-2025. The two drugs are not interchangeable substitutes; they answer different clinical questions, and the right choice depends on whether weight loss magnitude or confirmed cardiovascular risk reduction is the more urgent goal for a given patient.
The real decision here
The useful question is not simply "which drug works better," because the two drugs are not competing on the same endpoint. Tirzepatide wins decisively on weight loss and on A1C reduction in the trials where both classes have been studied against comparable GLP-1 agents. Dulaglutide currently has something tirzepatide does not: a completed, published cardiovascular outcomes trial. A patient with established atherosclerotic cardiovascular disease and a patient whose primary problem is obesity without cardiovascular disease are, in an evidence sense, being asked two different questions, and the two drugs answer them asymmetrically.
How the two drugs differ mechanistically
Tirzepatide's mechanism involves activation of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, whereas dulaglutide acts only on the GLP-1 receptor. The stronger weight loss and glycemic improvements seen with tirzepatide are thought to reflect this dual receptor engagement, but available head-to-head studies have not definitively quantified how much of this advantage comes from GIP activation versus differences in dosing schedules or maximum doses. This mechanistic account remains reasonable but unproven in any individual patient.
The FDA label for Zepbound includes adults with BMI at or above 30, or those with BMI 27 or higher and an associated condition such as hypertension, sleep apnea, or elevated lipids. Trulicity's approval covers type 2 diabetes treatment, and following a 2020 update, also cardiovascular event reduction in patients with both diabetes and either established heart disease or multiple cardiovascular risk factors. Notably, Trulicity has no approved indication for obesity. (U.S. Food and Drug Administration, Zepbound prescribing information, 2023: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf; Trulicity prescribing information, 2020: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf)
What the trial evidence shows
No published randomized trial has compared tirzepatide directly against dulaglutide with weight loss as the primary endpoint. The comparison below relies on separate trial programs rather than a head-to-head design, which limits how precisely the magnitude of difference can be stated.
Tirzepatide's obesity trial (SURMOUNT-1, published 2022). In adults without diabetes who had obesity or overweight with a weight-related condition, tirzepatide at its higher studied doses produced mean weight loss in the range of roughly 15 to 21 percent at 72 weeks, compared with roughly 3 percent for placebo. These figures are widely reported but should be verified against the original trial publication before being used in patient-facing materials, since exact percentages and confidence intervals matter for informed consent.
Tirzepatide versus semaglutide (SURPASS-2). In a head-to-head trial in people with type 2 diabetes, tirzepatide produced numerically larger A1C reductions and greater weight loss than semaglutide 1 mg. Because semaglutide has separately outperformed dulaglutide in other head-to-head diabetes trials, tirzepatide's advantage over dulaglutide can reasonably be inferred through this indirect chain, but it is an inference, not a direct comparison, and the size of the gap has not been measured in a trial that enrolled both drugs.
Dulaglutide's cardiovascular outcomes trial (REWIND, published 2019). In adults with type 2 diabetes, most of whom did not have established cardiovascular disease at baseline, dulaglutide 1.5 mg reduced the composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by roughly 12 percent in relative terms compared with placebo over a median follow-up of about 5 years. This is a completed, pre-specified cardiovascular outcome, which is a materially different kind of evidence than a weight-loss percentage from a shorter trial.
Tirzepatide's cardiovascular outcomes trial. A dedicated cardiovascular outcomes trial for tirzepatide has been running, but its primary MACE analysis had not been published as of mid-2025 to our knowledge. This means that, as of this writing, tirzepatide does not yet have the same category of confirmed cardiovascular protection evidence that dulaglutide has. This status should be re-checked at the time of publication of this article, since a completed trial readout would change this comparison materially.
Because the source material behind several of the precise percentages above could not be independently re-verified against a confirmed link at the time of drafting, editors should confirm exact figures (weight-loss percentages, A1C deltas, hazard ratios) against the primary trial publications before this article is published.
What real-world data add, and their limits
Clinical trial populations are selected and closely monitored, which tends to produce larger effects than routine practice. Multiple published real-world analyses using insurance claims or pharmacy fill data have reported that average weight loss and A1C improvement with both tirzepatide and dulaglutide run lower than trial results, and that a meaningful share of patients on either drug discontinue therapy within the first year, commonly citing GI side effects, cost, or insufficient effect. This directional pattern (real-world effect sizes below trial effect sizes, and substantial first-year discontinuation) is well supported across GLP-1-class real-world literature generally.
Specific numbers such as exact sample sizes, exact percentage weight loss at 12 months, or exact medication possession ratios are harder to state reliably here because the underlying study identifiers available for this draft could not be confirmed as matching the intended studies. Any real-world statistic used in the published version of this article should be attached to a verified, checked citation rather than restated from an unverified source chain.
Decision table: which factors should actually move your choice
| Decision factor | Favors Zepbound (tirzepatide) | Favors Trulicity (dulaglutide) | Evidence status |
|---|---|---|---|
| Primary goal is maximal weight loss | Yes, substantially larger effect size in obesity trials | No, modest effect, roughly single-digit percent | Trial evidence (SURMOUNT program); direct head-to-head vs dulaglutide not conducted |
| Established atherosclerotic cardiovascular disease, need proven MACE reduction now | Not yet, dedicated cardiovascular outcomes trial not finalized as of mid-2025 | Yes, completed cardiovascular outcomes trial (REWIND) | Trial evidence; re-check tirzepatide CVOT status before relying on this row |
| Formulary access without step therapy | Depends on plan; often more restricted | Often broader access, longer market history | Payer-dependent, changes over time; verify current formulary |
| A1C target is modest (roughly 1 percent reduction is sufficient) | More potent than needed, higher cost | Adequate for many patients at lower cost | Trial evidence from dulaglutide's diabetes program |
| Patient cannot tolerate wide dose titration or higher-dose GI effects | Titration range is wider (2.5 to 15 mg), more steps to manage | Narrower titration (0.75 to 1.5 mg), fewer adjustment points | Labeled dosing information |
| No obesity diagnosis, diabetes only, cost-sensitive | Not indicated for this population unless prescribed as Mounjaro | Approved, established option | FDA labeling |
The table above offers a structure for discussion with a treating clinician and should not replace case-by-case clinical reasoning. Many patients present with overlapping considerations (for instance, concurrent obesity and known heart disease), and in such instances the lack of tirzepatide cardiovascular outcomes data becomes the more pressing uncertainty pending results from tirzepatide's dedicated outcomes study.
Safety considerations that apply to both drugs
Both tirzepatide and dulaglutide carry black box warnings for thyroid C-cell proliferation identified in animal models, although translation to humans remains unclear, and both are avoided in patients with past or familial medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Pancreatitis represents a labeled adverse effect with both drugs; individuals with prior pancreatitis warrant a prescriber discussion before initiating therapy, and discontinuation is necessary if pancreatitis develops. Diabetic retinopathy progression has occurred during rapid blood sugar normalization with GLP-1 class medications; ophthalmologic baseline assessment and follow-up examination over the initial months represents prudent management for those with pre-existing retinopathy. (U.S. Food and Drug Administration prescribing information, both products, as cited above.)
Neither drug is FDA-labeled for use in combination with another GLP-1 receptor agonist, and combining a GLP-1 with a GIP/GLP-1 dual agonist is not an approved or studied approach. Seek urgent care for severe abdominal pain, persistent vomiting, signs of pancreatitis, or symptoms of a severe allergic reaction while on either drug.
Switching between the two drugs
Switching from dulaglutide to tirzepatide is typically done by starting tirzepatide at its lowest approved dose (2.5 mg once weekly) on the date the next dulaglutide dose would have been due, without a washout period, because both drugs have roughly similar elimination half-lives. This is a common clinical practice pattern rather than a specific numeric dose-conversion rule; there is no established equivalence ratio between the two drugs' doses, and titration should follow the tirzepatide label's schedule.
Switching from tirzepatide to dulaglutide is less common and is usually driven by cost, insurance coverage changes, or intolerance. Patients should be told plainly that weight loss will likely plateau or partially reverse on dulaglutide, since its effect on appetite and weight is smaller. Standard initiation is dulaglutide 0.75 mg weekly for several weeks before advancing to 1.5 mg, per the drug's label; no tapering of tirzepatide is required beforehand.
These are general practice patterns, not a substitute for a prescriber's individualized switching plan, and dosing decisions should not be made from this article alone.
Cost and coverage, as of when this was drafted
List prices and formulary placement change often enough that any number stated here needs a date attached and should be re-verified before publication. As a general pattern reported in the period around 2024 to 2025, tirzepatide-based products have carried a higher list price than dulaglutide, and dulaglutide has had a longer track record on commercial formularies, which can translate into fewer prior-authorization hurdles for some patients. Manufacturer savings programs can substantially change out-of-pocket cost for eligible commercially insured patients, and eligibility rules change.
Medicare coverage of anti-obesity medications, including Zepbound, has remained limited and plan-dependent; policy in this area has been actively evolving and should be checked against current CMS guidance rather than assumed.
What is established, what is plausible, and what is not established
Established: Tirzepatide produces substantially larger average weight loss than dulaglutide across separate trial programs, and it is FDA-approved for obesity while dulaglutide is not. Dulaglutide has a completed cardiovascular outcomes trial showing a reduction in major cardiovascular events in a population with type 2 diabetes and elevated cardiovascular risk.
Plausible but not proven at the individual level: That GIP co-agonism specifically (rather than dosing or titration differences) explains most of tirzepatide's larger effect size. That an individual patient's real-world weight loss or A1C response will match trial-level averages.
Not established as of this draft: Whether tirzepatide reduces major cardiovascular events, because its dedicated cardiovascular outcomes trial had not published a final primary analysis at the time of writing. Exact real-world adherence and effect-size percentages that could not be traced to a verified primary source in this draft; these require confirmation before publication.
Frequently asked questions
Frequently asked questions
Should I switch from Zepbound to Trulicity?
Is Zepbound stronger than Trulicity for weight loss?
Does Trulicity have a cardiovascular benefit that Zepbound does not have yet?
Can I take Zepbound and Trulicity at the same time?
Does Zepbound treat type 2 diabetes, or only obesity?
Is Trulicity cheaper than Zepbound?
References
- U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- U.S. Food and Drug Administration. Trulicity (dulaglutide) prescribing information, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s033lbl.pdf
- U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
Trial names referenced in the text (SURMOUNT-1, SURPASS-2, REWIND) are well-known published studies, but their specific numeric claims in this draft should be checked against the original journal publications and attached to verified DOIs or PMIDs before this article is finalized for publication.